Fig. 3: Time-to-event outcomes in the intent-to-treat population.

a Time to treatment failure—defined as time from randomization to death due to any cause, hematologic or major organ progression (evaluated according to central laboratory results and International Society of Amyloidosis criteria), clinically morbid organ disease requiring additional therapy, or withdrawal for any reason. Patients without documentation of treatment failure were censored at the date of last response assessment. b Time to subsequent therapy—defined as time from randomization to the start of subsequent anticancer treatment. Patients without subsequent anticancer therapy were censored at the date of death or the last date they were known to be alive. CI confidence interval, HR hazard ratio.